In a report released yesterday, Richard Close from Canaccord Genuity maintained a Buy rating on Quipt Home Medical (QIPT – Research Report), with a price target of $4.00.
Richard Close has given his Buy rating due to a combination of factors that highlight Quipt Home Medical’s strategic initiatives and growth potential. The company has outlined its 2025 strategic priorities, focusing on organic growth by strengthening patient referral relationships, expanding its footprint with new locations, and broadening its product portfolio while maintaining profit margins.
Additionally, Quipt is enhancing its sales force through a new training program aimed at increasing the effectiveness of its sales representatives. The company is also actively pursuing acquisitions and joint ventures with health systems, which could provide a steady flow of patients and improve post-acute care. These strategic moves, combined with the company’s commitment to share repurchase, suggest that Quipt is undervalued and has significant potential for future growth.
Based on the recent corporate insider activity of 17 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of QIPT in relation to earlier this year.